Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

被引:4
|
作者
Liu, Hangqi [1 ]
Zhang, Zhiwen [1 ]
Chen, Longyun [1 ]
Pang, Junyi [1 ]
Wu, Huanwen [1 ]
Liang, Zhiyong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol,State Key Lab Complex Severe & Rare D, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ovarian clear cell carcinoma; homologous recombination repair gene; homologous recombination deficiency; molecular classification; next-generation sequencing; EXPRESSION; VARIANTS;
D O I
10.3389/fonc.2021.798173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer
    Zsofia Sztupinszki
    Miklos Diossy
    Marcin Krzystanek
    Lilla Reiniger
    István Csabai
    Francesco Favero
    Nicolai J. Birkbak
    Aron C. Eklund
    Ali Syed
    Zoltan Szallasi
    npj Breast Cancer, 4
  • [42] Prevalence and clinical significance of pathogenic germline mutations in homologous recombination repair genes in Chinese lung cancer patients.
    Jiang, Yanxia
    Han, Liying
    Wang, Yan
    Wu, Nuoting
    Suo Peisu
    Huang, Tanxiao
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] Improved detection of homologous recombination deficiency in Chinese patients with ovarian cancer: a novel non-exonic single-nucleotide polymorphism-based next-generation sequencing panel
    Wei, Bing
    Zheng, Jinxiang
    Jiang, Cai
    Zhang, He
    Zhang, Mingye
    Cheng, Taoran
    Li, Jun
    Wang, Zhizhong
    Deng, Lijun
    Wang, Li
    Xia, Qingxin
    Ma, Jie
    MOLECULAR ONCOLOGY, 2023, 17 (08) : 1666 - 1677
  • [44] Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test
    Cristescu, Razvan
    Liu, Xiao Qiao
    Arreaza, Gladys
    Chen, Cai
    Albright, Andrew
    Qiu, Ping
    Marton, Matthew J.
    BMC CANCER, 2022, 22 (01)
  • [45] Homologous Recombination Deficiency (HRD) Phenotype Assessment Using Chromosomal Microarray (CMA) and 523-Gene Next-Generation Sequencing (NGS) Panel: A Comparative Analysis
    Vashisht, A.
    Kolhe, R.
    Mondal, A.
    Ahluwalia, P.
    Singh, H.
    Omar, N.
    Alptekin, A.
    Vashisht, V.
    Gupta, V.
    Williams, C.
    Srinivas, A.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (11): : S160 - S160
  • [46] Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
    Norquist, Barbara M.
    Brady, Mark F.
    Harrell, Maria I.
    Walsh, Tom
    Lee, Ming K.
    Gulsuner, Suleyman
    Bernards, Sarah S.
    Casadei, Silvia
    Burger, Robert A.
    Tewari, Krishnansu S.
    Backes, Floor
    Mannel, Robert S.
    Glaser, Gretchen
    Bailey, Cheryl
    Rubin, Stephen
    Soper, John
    Lankes, Heather A.
    Ramirez, Nilsa C.
    King, Mary Claire
    Birrer, Michael J.
    Swisher, Elizabeth M.
    CLINICAL CANCER RESEARCH, 2018, 24 (04) : 777 - 783
  • [47] Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes
    Sohn, Min-Hwan
    Kim, Se Ik
    Shin, Jong-Yeon
    Kim, Hee Seung
    Chung, Hyun Hoon
    Kim, Jae-Weon
    Lee, Maria
    Seo, Jeong-Sun
    GENES, 2021, 12 (07)
  • [48] Classification of high-grade serous ovarian carcinoma by epithelial-to-mesenchymal transition signature and homologous recombination repair genes
    Kim, Se Ik
    Kim, Jae-Weon
    Lee, Maria
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S109 - S110
  • [49] Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
    Choi, Min Chul
    Hwang, Sohyun
    Kim, Sewha
    Jung, Sang Geun
    Park, Hyun
    Joo, Won Duk
    Song, Seung Hun
    Lee, Chan
    Kim, Tae-Heon
    Kang, Haeyoun
    An, Hee Jung
    CANCER RESEARCH AND TREATMENT, 2020, 52 (02): : 634 - 644
  • [50] Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma
    Grigg, Claud
    Sha, Wei
    Bose, Rupali
    Neelands, Brittany
    Brown, Landon Carter
    Matulay, Justin T.
    Clark, Peter E.
    Burgess, Earle F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)